Bronchitis Treatment Market: Contours of Evolution

Companies investing in bronchitis treatment market are interested in studying the etiology of bronchitis. Key viruses are Influenza type A and B, while key bacterial agents are Streptococcus, Mycoplasma pneumonia, and Staphylococcus. There are several risk factors when population has high disposition to develop chronic bronchitis, particularly in regions where they are exposed to high environmental pollutants. The prevalence of bronchitis is high the general population. In chronic obstructive pulmonary disease (COPD) patients, the prevalence estimates can be as high as 54%. The high burden has been highlighted as a key driver for the evolution of the bronchitis treatment market.

Other key risk factors comprise tobacco smoking, increasing age, socioeconomic status, and occupational exposure. Both pharmacological and non-pharmacological interventions have gathered considerable attention among players in the bronchitis treatment market.

Key types comprise anti-inflammatory drugs, bronchodilators, and mucolytics.

A growing number of epidemiological studies has helped shed light on pharmacological interventions, spurring research on the above segments. The growing morbidity and mortality of acute and chronic bronchitis—the two types--is a key factor driving the bronchitis market.

The bronchitis market stood at US$ 3,432.62 million in 2017 and is projected to rise at CAGR of 3.6% from 2018 to 2026.

The report segments the bronchitis treatment market on the basis of region, type, drug class, and distribution channel.

bronchitis treatment market

Chronic bronchitis Segment Vie for Attention Among Researchers and Drug Makers

Among the two types, chronic bronchitis holds the leading share of the global market throughout the forecast period. The rise in the opportunities in this segment is the high morbidity and mortality rate. However, rate of developments in prognosis still seems tepid. Coordinated efforts made by all healthcare teams to improve the outcomes of pharmacological treatment for chronic is a key trend driving prospects in the bronchitis treatment market. Further, clinicians recommend making changes in lifestyle in reducing the morbidity of chronic bronchitis.

On the other hand, acute bronchitis is also garnering attention among drug makers and medical device manufacturers. The segment is expected to keep contributing significant revenues in coming years. In developed countries, given the high incidence, an array of studies have been done to understand the risk factors. These studies shed light on expected avenues in the bronchitis treatment market.

Growing Number of Clinical Trials Help Develop Novel Products

Over the years, nonpharmacological interventions have risen in popularity. The various drugs classes are antibiotics, bronchodilators, mucolytics, and, anti-inflammatory drugs. Of these, bronchodilators have been frequently recommended for the treatment of symptomatic COPD.

Advent of  novel LAMA/LABA fixed dose combination inhalers has helped in preventing the exacerbations in COPD patients. Thus, long-acting bronchodilators have attracted research targeted toward improving the mechanism. Growing number of clinical trials has helped develop long-acting bronchodilators. The findings of these studies have paved way to guidelines for reducing COPD exacerbations, thus unlocking new prospects for players in the bronchitis treatment market. Introduction of new drug regimens in COPD treatment options has expanded the horizon for stakeholders in the market. This has also led to the approval of novel LAMA/LABA fixed combinations, opening new doors to opportunities for market players.

Research in Bronchitis Therapeutics Makes North America Key Market

The key regional markets analysed in the study comprise North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, North America and Europe accounted for the major share of the global bronchitis treatment market in 2017. These regional markets have been fuelled by incessant research in bronchitis therapeutics to reduce the morbidity of the disease.

On the other hand, Asia Pacific is expected to be expand at remarkably high CAGR during 2018 – 2026. Several economies are witnessing marked progress in healthcare infrastructures to meet the demand for rising various patient populations. In particular, a robust impetus to the growth of the Asia Pacific bronchitis market comes from growing demand from elderly populations. In the cohort, smoking has been a key risk factor, in the light of other respiratory problems they may be facing. Further, the regional market has seen new avenues for growth due to extensive research and development done to reduce the morbidity of chronic bronchitis due to pollutants. High presence of pollutants in numerous developing economies in Asia has bolstered these research.

Growing Awareness of COPD and High Morbidity of Bronchitis Fuels Asia Pacific Market

Growing awareness of COPD in general population in developing economies is also a favorable trend in the expansion of potential opportunities in the bronchitis treatment market. On the other hand, there has been widespread efforts by governments in several of these nations to make public aware of the risk factors associated with cigarette smoking. Pharmaceutical companies have in recent years have come out with new non-pharmacological interventions, and the electronic media has been promoting the effectiveness of such treatments.

Asia Pacific is thus has large latent opportunities for developers of bronchodilators. The regional market is expected to clock CAGR of 4.0% from 2018 to 2026.

Companies extensively profiled in the report on the bronchitis treatment market are Boehringer Ingelheim International GmbH., Sanofi Aventis, Melinta Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Novartis AG, and AstraZeneca.

Global Bronchitis Treatment market: Overview 

This report analyzes the current and future scenario of the global bronchitis treatment market. Rise in geriatric population, high incidence of bronchitis, and increase in cigarette smoking patient pool are major drivers of the global market. 

The global bronchitis treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on type, drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global bronchitis treatment market. 

Global Bronchitis Treatment Market: Key Segments 

The global bronchitis treatment market has been segmented based on type, drug class, distribution channel, and region. Furthermore, in terms of type, the market has been divided into chronic bronchitis and acute bronchitis. The chronic bronchitis segment is likely to account for a leading share of the global market during the forecast period owing to high morbidity and mortality rate. Based on drug class, the bronchitis treatment market has been classified into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics. In terms of distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held a significant share of the market in 2017 due to a rise in the sale of over-the-counter bronchitis therapeutics. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Bronchitis Treatment Market: Regional Outlook 

In terms of region, the global bronchitis treatment market has been segmented into five major regions and key countries/sub-regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

The report also profiles major players in the global bronchitis treatment market based on various attributes such as company overview, financial overview, type portfolio, business strategies, and recent developments. Key players in the global bronchitis treatment market are AstraZeneca, Novartis AG, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Melinta Therapeutics, Sanofi Aventis, and Boehringer Ingelheim International GmbH.

The global bronchitis treatment market has been segmented as given below:

Type

  • Acute Bronchitis
  • Chronic Bronchitis

Drug Class

  • Antibiotics
  • Anti-inflammatory Drugs
  • Bronchodilators
  • Mucolytics

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Research Methodology 
     2.1. Assumptions and Acronyms Used
     2.2. Research Methodology

3. Executive Summary
     3.1. Global Bronchitis Treatment Market: Market Snapshot

4. Market Overview
     4.1. Global Bronchitis Treatment Market: Type Overview 
     4.2. Global Bronchitis Treatment Market: Key Industry Developments
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Bronchitis Treatment Market Revenue Projections, 2016–2026
     4.5. Porter’s Five Forces Analysis
     4.6. Global Bronchitis Treatment Market Outlook

5. Market Outlook
     5.1. Pipeline Analysis
     5.2. Key Market Trends
     5.3. Disease Epidemiology

6. Global Bronchitis Treatment Market Analysis, by Type
     6.1. Key Findings
     6.2. Introduction
     6.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Type
     6.4. Global Bronchitis Treatment Market Value Forecast, by Type
            6.4.1. Acute Bronchitis
            6.4.2. Chronic Bronchitis
     6.5. Global Bronchitis Treatment Market Analysis, by Type

7. Global Bronchitis Treatment Market Analysis and Forecast, by Drug Class
     7.1. Key Findings
     7.2. Introduction
     7.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Drug Class
     7.4. Global Bronchitis Treatment Market Value Forecast, by Drug Class
            7.4.1. Antibiotics
            7.4.2. Anti-inflammatory Drugs
            7.4.3. Bronchodilators
            7.4.4. Mucolytics
     7.5. Global Bronchitis Treatment Market Analysis, by Drug Class

8. Global Bronchitis Treatment Market Analysis, by Distribution Channel
     8.1. Key Findings
     8.2. Introduction
     8.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
     8.4. Global Bronchitis Treatment Market Value Forecast, by Distribution Channel
            8.4.1. Hospital Pharmacies
            8.4.2. Retail Pharmacies
            8.4.3. Online Pharmacies
     8.5. Global Bronchitis Treatment Market Analysis, by Distribution Channel

9. Global Bronchitis Treatment Market Analysis, by Region
     9.1. Global Bronchitis Treatment Market Scenario, by Country
     9.2. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Region
     9.3. Global Bronchitis Treatment Market Value Forecast, by Region
            9.3.1. North America
            9.3.2. Europe
            9.3.3. Asia Pacific 
            9.3.4. Latin America
            9.3.5. Middle East & Africa

10. North America Bronchitis Treatment Market Analysis
     10.1. Key Findings
     10.2. North America Bronchitis Treatment Market Overview
     10.3. North America Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Country
     10.4. North America Bronchitis Treatment Market Forecast, by Country
            10.4.1. U.S.
            10.4.2. Canada
     10.5. North America Bronchitis Treatment Market Value Share Analysis, by Type
     10.6. North America Bronchitis Treatment Market Forecast, by Type
            10.6.1. Acute Bronchitis
            10.6.2. Chronic Bronchitis
     10.7. North America Bronchitis Treatment Market Value Share Analysis, by Drug Class
     10.8. North America Bronchitis Treatment Market Forecast, by Drug Class
            10.8.1. Antibiotics
            10.8.2. Anti-inflammatory Drugs
            10.8.3. Bronchodilators
            10.8.4. Mucolytics
     10.9. North America Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
     10.10. North America Bronchitis Treatment Market Forecast, by Distribution Channel
            10.10.1. Hospital Pharmacies
            10.10.2. Retail Pharmacies
            10.10.3. Online Pharmacies
     10.11. North America Bronchitis Treatment Market Attractiveness Analysis

11. Europe Bronchitis Treatment Market Analysis
     11.1. Key Findings
     11.2. Europe Bronchitis Treatment Market Overview
     11.3. Europe Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
     11.4. Europe Bronchitis Treatment Market Forecast, by Country/Sub-region
            11.4.1. Germany
            11.4.2. U.K.
            11.4.3. France
            11.4.4. Italy
            11.4.5. Spain
            11.4.6. Rest of Europe
     11.5. Europe Bronchitis Treatment Market Value Share Analysis, by Type
     11.6. Europe Bronchitis Treatment Market Forecast, by Type
            11.6.1. Acute Bronchitis
            11.6.2. Chronic Bronchitis
     11.7. Europe Bronchitis Treatment Market Value Share Analysis, by Drug Class
     11.8. Europe Bronchitis Treatment Market Forecast, by Drug Class
            11.8.1. Antibiotics
            11.8.2. Anti-inflammatory Drugs
            11.8.3. Bronchodilators
            11.8.4. Mucolytics
     11.9. Europe Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
     11.10. Europe Bronchitis Treatment Market Forecast, by Distribution Channel
            11.10.1. Hospital Pharmacies
            11.10.2. Retail Pharmacies
            11.10.3. Online Pharmacies
     11.11. Europe Bronchitis Treatment Market Attractiveness Analysis

12. Asia Pacific Bronchitis Treatment Market Analysis
     12.1. Key Findings
     12.2. Asia Pacific Bronchitis Treatment Market Overview
     12.3. Asia Pacific Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
     12.4. Asia Pacific Bronchitis Treatment Market Forecast, by Country/Sub-region
            12.4.1. China
            12.4.2. India
            12.4.3. Japan
            12.4.4. Australia & New Zealand
            12.4.5. Rest of Asia Pacific
     12.5. Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Type
     12.6. Asia Pacific Bronchitis Treatment Market Forecast, by Type
            12.6.1. Acute Bronchitis
            12.6.2. Chronic Bronchitis
     12.7. Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Drug Class
     12.8. Asia Pacific Bronchitis Treatment Market Forecast, by Drug Class
            12.8.1. Antibiotics
            12.8.2. Anti-inflammatory Drugs
            12.8.3. Bronchodilators
            12.8.4. Mucolytics
     12.9. Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
     12.10. Asia Pacific Bronchitis Treatment Market Forecast, by Distribution Channel
            12.10.1. Hospital Pharmacies
            12.10.2. Retail Pharmacies
            12.10.3. Online Pharmacies
     12.11. Asia Pacific Bronchitis Treatment Market Attractiveness Analysis

13. Latin America Bronchitis Treatment Market Analysis
     13.1. Key Findings
     13.2. Latin America Bronchitis Treatment Market Overview
     13.3. Latin America Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
     13.4. Latin America Bronchitis Treatment Market Forecast, by Country/Sub-region
            13.4.1. Brazil
            13.4.2. Mexico
            13.4.3. Rest of Latin America
     13.5. Latin America Bronchitis Treatment Market Value Share Analysis, by Type
     13.6. Latin America Bronchitis Treatment Market Forecast, by Type
            13.6.1. Acute Bronchitis
            13.6.2. Chronic Bronchitis
     13.7. Latin America Bronchitis Treatment Market Value Share Analysis, by Drug Class
     13.8. Latin America Bronchitis Treatment Market Forecast, by Drug Class
            13.8.1. Antibiotics
            13.8.2. Anti-inflammatory Drugs
            13.8.3. Bronchodilators
            13.8.4. Mucolytics
     13.9. Latin America Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
     13.10. Latin America Bronchitis Treatment Market Forecast, by Distribution Channel
            13.10.1. Hospital Pharmacies
            13.10.2. Retail Pharmacies
            13.10.3. Online Pharmacies
     13.11. Latin America Bronchitis Treatment Market Attractiveness Analysis

14. Middle East & Africa Bronchitis Treatment Market Analysis
     14.1. Key Findings
     14.2. Middle East & Africa Bronchitis Treatment Market Overview
     14.3. Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region
     14.4. Middle East & Africa Bronchitis Treatment Market Forecast, by Country/Sub-region
            14.4.1. GCC Countries
            14.4.2. South Africa
            14.4.3. Rest of Middle East and Africa
     14.5. Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Type
     14.6. Middle East & Africa Bronchitis Treatment Market Forecast, by Type
            14.6.1. Acute Bronchitis
            14.6.2. Chronic Bronchitis
     14.7. Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Drug Class
     14.8. Middle East & Africa Bronchitis Treatment Market Forecast, by Drug Class
            14.8.1. Antibiotics
            14.8.2. Anti-inflammatory Drugs
            14.8.3. Bronchodilators
            14.8.4. Mucolytics
     14.9. Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
     14.10. Middle East & Africa Bronchitis Treatment Market Forecast, by Distribution Channel
            14.10.1. Hospital Pharmacies
            14.10.2. Retail Pharmacies
            14.10.3. Online Pharmacies
     14.11. Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis

15. Competition Landscape
     15.1. Bronchitis Treatment Market Share Analysis, by Company, 2017
     15.2. Competition Matrix
     15.3. Company Profiles
            15.3.1. AstraZeneca
                      15.3.1.1. Company Details
                      15.3.1.2. Business Overview
                      15.3.1.3. Financial Overview
                      15.3.1.4. Strategic Overview
                      15.3.1.5. SWOT Analysis
            15.3.2. Boehringer Ingelheim International GmbH
                      15.3.2.1. Company Details
                      15.3.2.2. Business Overview
                      15.3.2.3. Financial Overview
                      15.3.2.4. Strategic Overview
                      15.3.2.5. SWOT Analysis
            15.3.3. GlaxoSmithKline plc
                      15.3.3.1. Company Details
                      15.3.3.2. Business Overview
                      15.3.3.3. Financial Overview
                      15.3.3.4. Strategic Overview
                      15.3.3.5. SWOT Analysis
            15.3.4. Novartis AG
                      15.3.4.1. Company Details
                      15.3.4.2. Business Overview
                      15.3.4.3. Financial Overview
                      15.3.4.4. Strategic Overview
                      15.3.4.5. SWOT Analysis
            15.3.5. Melinta Therapeutics
                      15.3.5.1. Company Details
                      15.3.5.2. Business Overview
                      15.3.5.3. Financial Overview
                      15.3.5.4. Strategic Overview
                      15.3.5.5. SWOT Analysis
            15.3.6. Dr Reddy's Laboratories Ltd
                      15.3.6.1. Company Details
                      15.3.6.2. Business Overview
                      15.3.6.3. Financial Overview
                      15.3.6.4. Strategic Overview
                      15.3.6.5. SWOT Analysis
            15.3.7. Sanofi S.A.
                      15.3.7.1. Company Details
                      15.3.7.2. Business Overview
                      15.3.7.3. Financial Overview
                      15.3.7.4. Strategic Overview
                      15.3.7.5. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis
Table 02: Global Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 03: Global Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 04: Global Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 05: Global Bronchitis Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 06: North America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 07: North America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 08: North America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 09: North America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10: Europe Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country/Region 2016–2026
Table 11: Europe Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 12: Europe Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 13: Europe Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 14: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region 2016–2026
Table 15: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 16: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 17: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 18: Latin America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 19: Latin America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 20: Latin America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 21: Latin America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 22: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 23: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 24: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 25: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Bronchitis Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2026
Figure 02: Global Bronchitis Treatment Market Revenue Projection (US$ Mn), 2016–2026
Figure 03: Global Bronchitis Treatment Market Value Share, by Type, 2017
Figure 04: Global Bronchitis Treatment Market Value Share, by Drug Class, 2017
Figure 05: Global Bronchitis Treatment Market Value Share, by Region, 2017
Figure 06: Global Bronchitis Treatment Market Value Share, by Distribution Channel, 2017
Figure 07: Global Bronchitis Treatment Market Value Share Analysis by Type, 2017 and 2026
Figure 08: Global Bronchitis Treatment Market Attractiveness, by Type, 2018–2026
Figure 09: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Chronic Bronchitis, 2016–2026
Figure 10: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Acute Bronchitis, 2016–2026
Figure 11: Global Bronchitis Treatment Market Value Share Analysis by Drug Class, 2017 and 2026
Figure 12: Global Bronchitis Treatment Market Attractiveness, by Drug Class, 2018–2026
Figure 13: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Antibiotics, 2016–2026
Figure 14: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Anti-Inflammatory Drugs, 2016–2026
Figure 15: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Bronchodilators, 2016–2026
Figure 16: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Mucolytics, 2016–2026
Figure 17: Global Bronchitis Treatment Market Value Share, by Distribution Channel, 2017 and 2026
Figure 18: Global Bronchitis Treatment Market Attractiveness, by Distribution Channel, 2018–2026
Figure 19: Global Bronchitis Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 20: Global Bronchitis Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 21: Global Bronchitis Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2016-2026
Figure 22: Global Bronchitis Treatment Market Value Share, by Region, 2016 and 2025 
Figure 23: Global Bronchitis Treatment Market Attractiveness, by Region, 2018–2026
Figure 24: North America Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 25: North America Bronchitis Treatment Market Value Share Analysis, by Country, 2017 and 2026
Figure 26: North America Bronchitis Treatment Market Attractiveness Analysis, by Country, 2018-2026
Figure 27: North America Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 28: North America Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 29: North America Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 30: North America Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 31: North America Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 32: North America Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 33: Europe Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 34: Europe Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 35: Europe Bronchitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 36: Europe Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 37: Europe Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 38: Europe Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 39: Europe Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 40: Europe Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 41: Europe Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 42: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 43: Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 44: Asia Pacific Bronchitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 45: Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 46: Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 47: Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 48: Asia Pacific Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 49: Asia Pacific Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 50: Asia Pacific Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 51: Latin America Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 52: Latin America Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 53: Latin America Bronchitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 54: Latin America Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 55: Latin America Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 56: Latin America Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 57: Latin America Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 58: Latin America Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 59: Latin America Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 60: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 61: Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 62: Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 63: Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 64: Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 65: Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 66: Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 67: Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 68: Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 69: Global Bronchitis Treatment Market Share, by Company, 2017
Figure 70: AstraZeneca Breakdown of Net Sales (%), by Region, 2017
Figure 71: AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 72: AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2017
Figure 73: Boehringer Ingelheim International GmbH, Human Pharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 74: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2017
Figure 75: Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 76: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2017
Figure 77: GlaxoSmithKline plc Respiratory Business Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 78: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2017
Figure 80: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2017
Figure 81: Novartis AG COPD Portfolio Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 82: Novartis AG Breakdown of Net Sales (%), by Country, 2017
Figure 83: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 84: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2017
Figure 85: Melinta Therapeutics Respiratory Medicine Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 86: Melinta Therapeutics Breakdown of Net Sales (%), by Region, 2017
Figure 87: Melinta Therapeutics R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 88: Melinta Therapeutics Breakdown of Net Sales (%), by Business Segment, 2017
Figure 89: Dr Reddy's Laboratories Ltd., Ltd Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 90: Dr Reddy's Laboratories Ltd., Breakdown of Net Sales (%), by Region, 2017
Figure 91: Dr Reddy's Laboratories Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 92: Dr Reddy's Laboratories Ltd., Breakdown of Net Sales (%), by Product Segment, 2017
Figure 93: Sanofi S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 94: Sanofi S.A. Breakdown of Net Sales (%), by Region, 2017
Figure 95: Sanofi S.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 96: Sanofi S.A. Breakdown of Net Sales (%), by Therapeutics Area, 2017

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Bronchitis Treatment Market